- Home
- OBE vs ZVRA Comparison
OBE vs ZVRA Comparison
Compare OBE & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | ZVRA |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.8M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | OBE | ZVRA |
|---|---|---|
| Price | $7.42 | $8.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $21.71 |
| AVG Volume (30 Days) | 560.6K | ★ 827.5K |
| Earning Date | 02-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | ★ $441,312,666.00 | $84,388,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $15.82 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $3.88 | $6.19 |
| 52 Week High | $8.10 | $13.16 |
Technical Indicators
Market Signals| Indicator | OBE | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 47.35 |
| Support Level | $7.25 | $8.25 |
| Resistance Level | $7.55 | $8.73 |
| Average True Range (ATR) | 0.40 | 0.43 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 50.15 | 25.91 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.